Comprehensive AIDS Research Center and Research Center for Public Health, School of Medicine, Tsinghua University, Beijing, China.
Research Center for Biological Therapy, Beijing Institute of Infectious Diseases, Beijing, China.
J Dig Dis. 2020 Jun;21(6):315-318. doi: 10.1111/1751-2980.12883.
Intestinal fibrosis is a common complication of inflammatory bowel disease (IBD), resulting in strictures and ultimately obstruction, which is a significant clinical problem. Fibrosis is mainly triggered by local chronic inflammation and occurs when excessive extracellular matrix deposition is caused by activated mesenchymal cells. Despite the advance of anti-inflammatory therapies in IBD, the incidence and preventive strategies of intestinal fibrosis and strictures in IBD have not significantly changed over time. This shows that inflammation is necessary for fibrosis, but it does not necessarily affect the fibrotic progression. This review summarizes current knowledge about the non-inflammatory mechanisms implicated in the gut fibrotic process of IBD, which may pave the way for new mechanisms and anti-fibrotic therapies.
肠纤维化是炎症性肠病(IBD)的常见并发症,可导致狭窄并最终发生梗阻,这是一个重大的临床问题。纤维化主要由局部慢性炎症引发,当激活的间充质细胞引起细胞外基质过度沉积时发生。尽管 IBD 的抗炎治疗取得了进展,但肠纤维化和狭窄的发生率和预防策略并没有随时间显著改变。这表明炎症是纤维化的必要条件,但不一定会影响纤维化的进展。本综述总结了目前关于 IBD 肠道纤维化过程中涉及的非炎症机制的知识,这可能为新的机制和抗纤维化治疗铺平道路。
J Dig Dis. 2020-6
Eur Rev Med Pharmacol Sci. 2013-5
Scand J Gastroenterol. 2015-1
J Dig Dis. 2020-6
J Crohns Colitis. 2019-4-26
Immunol Rev. 2021-7
Dig Dis. 2013-9-6
Eur J Med Res. 2024-6-18
J Clin Med. 2023-4-22
Nat Rev Gastroenterol Hepatol. 2022-3
Expert Rev Gastroenterol Hepatol. 2021-4